OMIC Singular Genomics Systems, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $2.67M and net income of −$86.3M.
OMIC revenue and earnings
- Quarter ended Sep 30, 2024: revenue $406K, net income −$16.8M, EPS -6.72
- Quarter ended Jun 30, 2024: revenue $737K, net income −$21.3M, EPS -8.57
- Quarter ended Mar 31, 2024: revenue $442K, net income −$25.0M, EPS -0.34
- Quarter ended Dec 31, 2023: revenue $1.08M, net income −$23.2M, EPS 18.86
Recent OMIC insider trades
- Feb 14, 2025: Spaventa Andrew sold 800 shares ($15.9K)
- Dec 16, 2024: Spaventa Andrew sold 180 shares ($3.63K)
- Nov 12, 2024: Spaventa Andrew sold 695 shares ($15.7K)
5%+ owners
- Deerfield Mgmt IV, L.P.: 100.0% (Schedule 13D/A, filed Feb 25, 2025)
Are insiders buying or selling OMIC?
No open-market insider buys or sells of Singular Genomics Systems, Inc. were reported in the last 12 months.
What was OMIC's revenue last quarter?
Singular Genomics Systems, Inc. reported revenue of $406K for the quarter ended September 30, 2024, with net income of −$16.8M.